An open-label trial of rituximab therapy in pulmonary alveolar proteinosis

European Respiratory Journal

Volumn 38, Issue 6, 2011, Pages 1361-1367

  Kavuru, M S ^a   Malur, A ^a   Marshall, I ^a   Barna, B P ^a   Meziane, M ^b   Huizar, I ^a   Dalrymple, H ^a   Karnekar, R ^a   Thomassen, M J ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

B cells; Bronchoalveolar lavage; Pulmonary alveolar proteinosis; Rituximab

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; RITUXIMAB;

ADULT; AGED; ANOREXIA; ARTERIAL BLOOD; ARTICLE; B LYMPHOCYTE; BLOOD OXYGENATION; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG ALVEOLUS PROTEINOSIS; LUNG FUNCTION; LUNG LAVAGE; MALE; NAUSEA; NOSE CONGESTION; OXYGEN TENSION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; BRONCHOALVEOLAR LAVAGE FLUID; COHORT STUDIES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LUNG; MALE; MIDDLE AGED; OXYGEN; PULMONARY ALVEOLAR PROTEINOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82555172978     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00197710     Document Type: Article

References (38)

1. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26: Suppl. 14, 66-73. (Pubitemid 29523413)
2. Anolik JI, Sanz, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 2003; 5: 350-356.
3. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581. (Pubitemid 38758544)
4. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232.
5. Cambridge G, LeandroMJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-2154. (Pubitemid 36959194)
6. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 450-454. (Pubitemid 24272191)
7. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264: 713-716. (Pubitemid 24185882)
8. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994; 91: 5592-5596. (Pubitemid 24174374)
9. Huizar I, Kavuru MS. Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Curr Opin Pulm Med 2009; 15: 491-498.
10. Thomassen MJ, Yi T, Raychaudhuri B, et al. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000; 95: 85-92. (Pubitemid 30317817)
11. Carraway MS, Ghio AJ, Carter JD, et al. Detection of granulocyte- macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161: 1294-1299. (Pubitemid 30243844)
12. Kitamura TN, Tanaka J, Watanabe K, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190: 875-880.
13. Tanaka NJ, Watanabe T, Kitamura Y, et al. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony-stimulating factor. FEBS Lett 1999; 442: 246-250.
14. Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105: 342-350. (Pubitemid 36016062)
15. Bonfield TL, Russell D, Burgess S, et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27: 481-486.
16. Seymour JF, Doyle IR, Nakata K, et al. Relationship of anti-GMCSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003; 58: 252-257. (Pubitemid 36308005)
17. Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 162: 658-662. (Pubitemid 30647215)
18. Mahler DA, Waterman LA, Ward J, et al. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnoea indexes. Chest 2007; 132: 1283-1290. (Pubitemid 47621005)
19. Akira MG, Inoue S, Yamamoto, et al. Non-specific interstitial pneumonia: findings on sequential CT scans of nine patients. Thorax 2000; 55: 854-859.
20. Tazawa RB, Trapnell C, Inoue Y, et al. Inhaled granulocyte/ macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010; 181: 1345-1354.
21. Thomassen MJ, Buhrow LT, Connors MJ, et al. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol 1997; 17: 279-283. (Pubitemid 127500831)
22. Bonfield TL, John N, Barna BP, et al. Multiplexed particle-based anti-granulocyte macrophage colony stimulating factor (GM-CSF) assay used as pulmonary diagnostic test. Clin Diagn Lab Immunol 2005; 12: 821-824. (Pubitemid 40993280)
23. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis (progress in the first 44 years). Am J Respir Crit Care Med 2002; 166: 215-235. (Pubitemid 34765459)
24. Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006; 130: 227-237. (Pubitemid 44116865)
25. Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg 2009; 6: 13-19.
26. Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophagecolony- stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009; 113: 2547-2556.
27. Kavuru MS, Bonfield TL, Thomassen MJ. Plasmapheresis, GM-CSF, and alveolar proteinosis. Am J Respir Crit Care Med 2003; 167: 1036.
28. Luisetti M, Rodi G, Perotti C, et al. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 2009; 33: 1220-1222.
29. Borie R, Debray MP, Laine C, et al. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009; 33: 1503-1506.
30. Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177: 752-762. (Pubitemid 351490562)
31. Zeimpekoglou K. The role of B-lymphocytes in lung disease. Pneumon 2008; 21: 196-199.
32. Bonfield TL, Barna BP, John N, et al. Suppression of activin A in autoimmune lung disease associated with anti-GM-CSF. J Autoimmun 2006; 26: 37-41. (Pubitemid 43138891)
33. Sakagami T, Beck D, Uchida K, et al. Patient-derived granulocyte/ macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med 2010; 182: 49-61.
34. Sakagami T, Uchida K, Suzuki T, et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 2010; 361: 2679-2681.
35. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 62-74. (Pubitemid 46026695)
36. Perosa F, Prete M, Racanelli V, et al. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010; 267: 260-277.
37. Leandro MJ, de la Torre I. Translational mini-review series on B cell-directed therapies: the pathogenic role of B cells in autoantibody- associated autoimmune diseases - lessons from B cell-depletion therapy. Clin Exp Immunol 2009; 157: 191-197.
38. Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007; 179: 3351-3361.